## Jennifer Le

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5598342/publications.pdf

Version: 2024-02-01

279487 253896 2,093 43 23 43 h-index citations g-index papers 44 44 44 2139 docs citations times ranked citing authors all docs

#	ARTICLE Therepoulte monitoring of vancomycle for cerious motherille registant (1) Stanbylogoccus	IF	Citations
1	Therapeutic monitoring of vancomycin for serious methicillin-resistant (1) Staphylococcus aureus (1) infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. American Journal of	0.5	640
2	Improved Vancomycin Dosing in Children Using Area Under the Curve Exposure. Pediatric Infectious Disease Journal, 2013, 32, e155-e163.	1.1	199
3	Incidence and Risk Factors Influencing the Development of Vancomycin Nephrotoxicity in Children. Journal of Pediatrics, 2011, 158, 422-426.	0.9	161
4	Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clinical Infectious Diseases, 2020, 71, 1361-1364.	2.9	142
5	Pharmacodynamic Characteristics of Nephrotoxicity Associated With Vancomycin Use in Children. Journal of the Pediatric Infectious Diseases Society, 2015, 4, e109-e116.	0.6	82
6	Consensus Summary of Aerosolized Antimicrobial Agents: Application of Guideline Criteria. Pharmacotherapy, 2010, 30, 562-584.	1.2	77
7	Characterization of the Population Pharmacokinetics of Ampicillin in Neonates Using an Opportunistic Study Design. Antimicrobial Agents and Chemotherapy, 2014, 58, 3013-3020.	1.4	62
8	A Formal Mentorship Program for Faculty Development. American Journal of Pharmaceutical Education, 2014, 78, 100.	0.7	56
9	Augmented Renal Clearance Using Population-Based Pharmacokinetic Modeling in Critically Ill Pediatric Patients*. Pediatric Critical Care Medicine, 2017, 18, e388-e394.	0.2	56
10	Antimicrobial Susceptibility of Streptococcus pneumoniae from North America, Europe, Latin America, and the Asia-Pacific Region: Results From 20 Years of the SENTRY Antimicrobial Surveillance Program (1997–2016). Open Forum Infectious Diseases, 2019, 6, S14-S23.	0.4	56
11	Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillina Resistant <i>Staphylococcus aureus /i&gt; Infections: A Revised Consensus Guideline and Review of the American Society of Healthâ System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy,</i>	1.2	56
12	Treatment of Meningitis Caused by Vancomycin-Resistant Enterococcus faecium: High-Dose and Combination Daptomycin Therapy. Annals of Pharmacotherapy, 2010, 44, 2001-2006.	0.9	43
13	Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis. Infectious Diseases and Therapy, 2021, 10, 687-697.	1.8	38
14	Optimizing Antibiotic Drug Therapy in Pediatrics: Current State and Future Needs. Journal of Clinical Pharmacology, 2018, 58, S108-S122.	1.0	37
15	Vancomycin Monitoring in Children Using Bayesian Estimation. Therapeutic Drug Monitoring, 2014, 36, 510-518.	1.0	35
16	Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 281-284.	0.6	33
17	Aerosolized Delivery of Antifungal Agents. Current Fungal Infection Reports, 2010, 4, 96-102.	0.9	32
18	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. Clinical Pharmacokinetics, 2020, 59, 1195-1216.	1.6	28

#	Article	IF	CITATIONS
19	In Vitro Activity of Carbapenems Alone and in Combination With Amikacin Against KPC-Producing Klebsiella Pneumoniae. Journal of Clinical Medicine Research, 2011, 3, 106-10.	0.6	28
20	Complications Associated With Outpatient Parenteral Antibiotic Therapy in Children. Clinical Pediatrics, 2010, 49, 1038-1043.	0.4	27
21	Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients. Journal of Oncology Pharmacy Practice, 2016, 22, 448-453.	0.5	27
22	Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing. Pharmacotherapy, 2017, 37, 361-378.	1.2	26
23	Bayesian Estimation of Vancomycin Pharmacokinetics in Obese Children: Matched Case-Control Study. Clinical Therapeutics, 2015, 37, 1340-1351.	1.1	24
24	Clonal Dissemination of <i>Klebsiella pneumoniae</i> Carbapenemase KPC-3 in Long Beach, California. Journal of Clinical Microbiology, 2010, 48, 623-625.	1.8	15
25	Pharmacokinetics of singleâ€dose ceftaroline fosamil in children with cystic fibrosis. Pediatric Pulmonology, 2017, 52, 1424-1434.	1.0	15
26	Population-Based Pharmacokinetic Modeling of Vancomycin in Children with Renal Insufficiency. Journal of Pharmacology & Clinical Toxicology, 2014, 2, 1017-1026.	0.5	13
27	Use of Simulation Strategies to Predict Subtherapeutic Meropenem Exposure Caused by Augmented Renal Clearance in Critically Ill Pediatric Patients With Sepsis. Journal of Pediatric Pharmacology and Therapeutics, 2020, 25, 413-422.	0.3	11
28	Comparative Analysis of Ampicillin Plasma and Dried Blood Spot Pharmacokinetics in Neonates. Therapeutic Drug Monitoring, 2018, 40, 103-108.	1.0	9
29	Augmented renal clearance of aminoglycosides using population-based pharmacokinetic modelling with Bayesian estimation in the paediatric ICU. Journal of Antimicrobial Chemotherapy, 2020, 75, 162-169.	1.3	9
30	Implementation of Vancomycin Therapeutic Monitoring Guidelines: Focus on Bayesian Estimation Tools in Neonatal and Pediatric Patients. Therapeutic Drug Monitoring, 2022, 44, 241-252.	1.0	8
31	Prolonged Post-Discontinuation Antibiotic Exposure in Very Low Birth Weight Neonates at Risk for Early-Onset Sepsis. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 615-621.	0.6	7
32	Case report of transient mcr-1 -haboring Escherichia coli with concurrent Staphylococcus aureus bacteremia in Long Beach, California. Diagnostic Microbiology and Infectious Disease, 2017, 89, 303-304.	0.8	6
33	Optimizing Aminoglycoside Dosing Regimens for Critically III Pediatric Patients with Augmented Renal Clearance: a Convergence of Parametric and Nonparametric Population Approaches. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	6
34	Time to Initiation of Antifungal Therapy for Neonatal Candidiasis. Antimicrobial Agents and Chemotherapy, 2013, 57, 2550-2555.	1.4	5
35	Paradoxical Antibiotic Effect of Ampicillin. Pediatric Infectious Disease Journal, 2020, 39, 725-729.	1.1	5
36	Antimicrobial prescribing for treatment of serious infections caused by Staphylococcus aureus and methicillin-resistant Staphylococcus aureus in pediatrics: an expert review. Expert Review of Anti-Infective Therapy, 2021, 19, 1107-1116.	2.0	5

#	Article	IF	CITATIONS
37	Ampicillin dosing in premature infants for early-onset sepsis: exposure-driven efficacy, safety, and stewardship. Journal of Perinatology, 2022, 42, 959-964.	0.9	4
38	Comment on: AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics. Journal of Antimicrobial Chemotherapy, 2021, 76, 2486-2488.	1.3	3
39	Vancomycin therapeutic monitoring by measured trough concentration versus Bayesianâ€derived area under the curve in critically ill patients with cancer. Pharmacology Research and Perspectives, 2022, 10, e00912.	1.1	3
40	Case-control study of risk factors and outcomes associated with neonatal candidiasis. Journal of Neonatal-Perinatal Medicine, 2011, 4, 39-43.	0.4	1
41	Cost-effective analysis of low- versus high-dose colistin in the treatment of multi-drug resistant pneumonia in Saudi Arabia. International Journal of Clinical Pharmacy, 2019, 41, 1-2.	1.0	1
42	Questions on Vancomycin Dosing. Clinical Infectious Diseases, 2020, 73, e1777-e1778.	2.9	1
43	Emerging Viral and Bacterial Infections: Within an Era of Opioid Epidemic. Infectious Diseases and Therapy, 2020, 9, 737-755.	1.8	1